1-O-β-D-Glucopyranosyl-N-hexadecanoylsphingosine manufacturers
|
| | 1-O-β-D-Glucopyranosyl-N-hexadecanoylsphingosine Basic information |
| Product Name: | 1-O-β-D-Glucopyranosyl-N-hexadecanoylsphingosine | | Synonyms: | (2S,3R,4E)-2-(Hexadecanoylamino)-1-(β-D-glucopyranosyloxy)-4-octadecen-3-ol;1-O-β-D-Glucopyranosyl-N-hexadecanoylsphingosine;1-O-β-D-Glucopyranosyl-N-palmitoylsphingosine;C16:0-GlcCer;C16:0-GluCer;D-erythro-N-Palmitoyl-glucosyl-C18-Sphingosine;D-glucosyl--1,1' N-palMitoyl-D-erythro-sphingosine;D-Glucosyl-β-1,1'-N-palmitoylsphingosine | | CAS: | 74365-77-8 | | MF: | C40H77NO8 | | MW: | 700.04 | | EINECS: | | | Product Categories: | | | Mol File: | 74365-77-8.mol |  |
| | 1-O-β-D-Glucopyranosyl-N-hexadecanoylsphingosine Chemical Properties |
| solubility | Methanol: Sparingly soluble: 1-10 mg/ml | | form | Solid | | color | White to off-white | | InChIKey | VJLLLMIZEJJZTE-NNTBDIJYSA-N | | SMILES | [H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O |
| Storage Class | 11 - Combustible Solids |
| | 1-O-β-D-Glucopyranosyl-N-hexadecanoylsphingosine Usage And Synthesis |
| Uses | D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity[1]. | | Definition | ChEBI: Beta-D-glucosyl-N-hexadecanoylsphingosine is a beta-D-glucosyl-N-acylsphingosine in which the acyl group is specified as hexadecanoyl. It has a role as a mouse metabolite. It is functionally related to a hexadecanoic acid. | | References | [1] Nagata M, et, al. Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity. Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3285-E3294. DOI:10.1073/pnas.1618133114
[2] BARBARA KOVACIC. Glucosylceramide Critically Contributes to the Host Defense of Cystic Fibrosis Lungs.[J]. Cellular Physiology and Biochemistry, 2017, 41 3: 1208-1218. DOI: 10.1159/000464382
[3] MICHELLE M MIELKE. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: a pilot study.[J]. PLoS ONE, 2013: e73094. DOI: 10.1371/journal.pone.0073094
[4] WILLIAM L HOLLAND Scott A S. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.[J]. Endocrine reviews, 2008, 29 4: 381-402. DOI: 10.1210/er.2007-0025 |
| | 1-O-β-D-Glucopyranosyl-N-hexadecanoylsphingosine Preparation Products And Raw materials |
|